| Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review J Sousa, G Alves, A Fortuna, A Falcao Analytical and bioanalytical chemistry 403, 93-129, 2012 | 105 | 2012 |
| Handling interoccasion variability in model‐based dose individualization using therapeutic drug monitoring data JA Abrantes, S Jönsson, MO Karlsson, EI Nielsen British journal of clinical pharmacology 85 (6), 1326-1336, 2019 | 58 | 2019 |
| Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients AW Oosten, JA Abrantes, S Jönsson, P de Bruijn, EJM Kuip, A Falcão, ... European journal of clinical pharmacology 72, 459-467, 2016 | 33 | 2016 |
| Elucidation of factor VIII activity pharmacokinetics: a pooled population analysis in patients with hemophilia A treated with moroctocog alfa JA Abrantes, EI Nielsen, J Korth‐Bradley, L Harnisch, S Jönsson Clinical Pharmacology & Therapeutics 102 (6), 977-988, 2017 | 29 | 2017 |
| Herb–drug interaction of Fucus vesiculosus extract and amiodarone in rats: A potential risk for reduced bioavailability of amiodarone in clinical practice M Rodrigues, G Alves, J Abrantes, A Falcão Food and chemical toxicology 52, 121-128, 2013 | 26 | 2013 |
| Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients JA Abrantes, A Solms, D Garmann, EI Nielsen, S Jönsson, MO Karlsson haematologica 105 (5), 1443, 2020 | 25 | 2020 |
| A prospective population pharmacokinetic study on morphine metabolism in cancer patients AW Oosten, JA Abrantes, S Jönsson, M Matic, RHN van Schaik, ... Clinical pharmacokinetics 56, 733-746, 2017 | 21 | 2017 |
| Bayesian forecasting utilizing bleeding information to support dose individualization of factor VIII JA Abrantes, A Solms, D Garmann, EI Nielsen, S Jönsson, MO Karlsson CPT: Pharmacometrics & Systems Pharmacology 8 (12), 894-903, 2019 | 11 | 2019 |
| Integrated modelling of factor VIII activity kinetics, occurrence of bleeds and individual characteristics in haemophilia a patients using a full random effects modelling (FREM … J Abrantes, A Solms, D Garmann, EI Nielsen, S Jonsson, MO Karlsson | 5 | 2018 |
| Handling inter‐occasion variability in model‐based therapeutic drug monitoring J Abrantes, S Jönsson, MO Karlsson, EI Nielsen Annual Meeting of the Population Approach Group in Europe, Budapest, Hungary …, 2017 | 3 | 2017 |
| A repeated time-to-event model for epileptic seizures in patients undergoing antiepileptic drug withdrawal during video-electroencephalography monitoring JA Abrantes, A Almeida, F Sales, A Falcão, S Jonsson PAGE abstracts of the annual meeting of the population approach group in …, 2014 | 3 | 2014 |
| Pharmacometric Approaches to Improve Dose Individualization Methods in Hemophilia A JA Abrantes Acta Universitatis Upsaliensis, 2019 | 1 | 2019 |
| Fentanyl exposure after subcutaneous and transdermal administration: Results from a population pharmacokinetic study in cancer patients. AW Oosten, JA Abrantes, S Jönsson, P de Bruijn, W Ghidey Alemayehu, ... Journal of Clinical Oncology 32 (15_suppl), 9540-9540, 2014 | 1 | 2014 |
